Danicamtiv

Cat. No.:	HY-109128			
CAS No.:	1970972-74-7			
Molecular Formula:	$C_{16}H_{20}F_{3}N_{5}O_{4}S$			
Molecular Weight:	435.42			
Target:	Myosin			
Pathway:	Cytoskeleton			
Storage:	Powder	-20°C	3 years	
		4°C	2 years	
	In solvent	-80°C	2 years	
		-20°C	1 year	

®

MedChemExpress

SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (11	DMSO : 50 mg/mL (114.83 mM; Need ultrasonic)					
Preparing Stock Solutions		Solvent Mass Concentration	1 mg	5 mg	10 mg		
	Preparing Stock Solutions	1 mM	2.2966 mL	11.4832 mL	22.9663 mL		
		5 mM	0.4593 mL	2.2966 mL	4.5933 mL		
	10 mM	0.2297 mL	1.1483 mL	2.2966 mL			
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.74 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.74 mM); Clear solution						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.74 mM); Clear solution						

Description	Danicamtiv (MYK-491), an inotropic agent, is a selective allosteric activator of cardiac myosin. Danicamtiv increases cardiac systolic function and preserves mechanical efficiency ^[1] .				
In Vivo	Danicamtiv selectively enhances cardiac actomyosin activity, the molecular force⊠generating unit of the sarcomere, prolonging contraction while preserving actin–myosin detachment, allowing relaxation, and without impacting Ca ²⁺ homeostasis ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.				

Product Data Sheet

`F ₽

o F

N-0

N H

REFERENCES

[1]. Sarah Fernandes, et al. Abstract 15707: MYK-491, a Novel Small-Molecule Cardiac Myosin Activator Increases Cardiac Systolic Function and Preserves Mechanical Efficiency: Pre-Clinical in vivo and in vitro Evidence. Circulation. 2019;140:A15707

[2]. Voors AA, et al. Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. Eur J Heart Fail. 2020;22(9):1649-1658.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA